Literature DB >> 23172308

1p36 tumor suppression--a matter of dosage?

Kai-Oliver Henrich1, Manfred Schwab, Frank Westermann.   

Abstract

A broad range of human malignancies is associated with nonrandom 1p36 deletions, suggesting the existence of tumor suppressors encoded in this region. Evidence for tumor-specific inactivation of 1p36 genes in the classic "two-hit" manner is scarce; however, many tumor suppressors do not require complete inactivation but contribute to tumorigenesis by partial impairment. We discuss recent data derived from both human tumors and functional cancer models indicating that the 1p36 genes CHD5, CAMTA1, KIF1B, CASZ1, and miR-34a contribute to cancer development when reduced in dosage by genomic copy number loss or other mechanisms. We explore potential interactions among these candidates and propose a model where heterozygous 1p36 deletion impairs oncosuppressive pathways via simultaneous downregulation of several dosage-dependent tumor suppressor genes.

Entities:  

Mesh:

Year:  2012        PMID: 23172308     DOI: 10.1158/0008-5472.CAN-12-2230

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  Collateral Lethality: A new therapeutic strategy in oncology.

Authors:  Florian L Muller; Elisa A Aquilanti; Ronald A DePinho
Journal:  Trends Cancer       Date:  2015-11-01

2.  CASZ1 inhibits cell cycle progression in neuroblastoma by restoring pRb activity.

Authors:  Zhihui Liu; Julieann Rader; Stanley He; Tanya Phung; Carol J Thiele
Journal:  Cell Cycle       Date:  2013-07-15       Impact factor: 4.534

Review 3.  The role of noncoding RNAs in epithelial cancer.

Authors:  Massimiliano Agostini; Carlo Ganini; Eleonora Candi; Gerry Melino
Journal:  Cell Death Discov       Date:  2020-03-12

Review 4.  The Chromodomain Helicase DNA-Binding Chromatin Remodelers: Family Traits that Protect from and Promote Cancer.

Authors:  Alea A Mills
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

Review 5.  Role of CHD5 in human cancers: 10 years later.

Authors:  Venkatadri Kolla; Tiangang Zhuang; Mayumi Higashi; Koumudi Naraparaju; Garrett M Brodeur
Journal:  Cancer Res       Date:  2014-01-13       Impact factor: 12.701

6.  An overview of neuroblastoma cell lineage phenotypes and in vitro models.

Authors:  Sheron Campos Cogo; Thatyanne Gradowski Farias da Costa do Nascimento; Fernanda de Almeida Brehm Pinhatti; Nilton de França Junior; Bruna Santos Rodrigues; Luciane Regina Cavalli; Selene Elifio-Esposito
Journal:  Exp Biol Med (Maywood)       Date:  2020-08-12

7.  Polymorphisms in the kinesin-like factor 1 B gene and risk of epithelial ovarian cancer in Eastern Chinese women.

Authors:  Ting-Yan Shi; Zhi Jiang; Rong Jiang; Sheng Yin; Meng-Yun Wang; Ke-Da Yu; Zhi-Ming Shao; Meng-Hong Sun; Rongyu Zang; Qingyi Wei
Journal:  Tumour Biol       Date:  2015-04-09

8.  The Microtubule Network and Cell Death Are Regulated by an miR-34a/Stathmin 1/βIII-Tubulin Axis.

Authors:  Nancy S Vetter; E A Kolb; Christopher C Mills; Valerie B Sampson
Journal:  Mol Cancer Res       Date:  2017-03-08       Impact factor: 5.852

9.  Steroid receptor-associated and regulated protein is a biomarker in predicting the clinical outcome and treatment response in malignancies.

Authors:  Ali Naderi
Journal:  Cancer Rep (Hoboken)       Date:  2020-07-24

10.  HPV E6/p53 mediated down-regulation of miR-34a inhibits Warburg effect through targeting LDHA in cervical cancer.

Authors:  Rong Zhang; Jing Su; Song-Lin Xue; Hui Yang; Li-Li Ju; Ying Ji; Kai-Hua Wu; Yan-Wei Zhang; Ye-Xin Zhang; Jian-Fang Hu; Min-Min Yu
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.